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The aim of this study was to clarify whether common single nucleotide polymorphisms (SNPs) of the Peroxisome
Proliferator-Activated Receptor-γ (PPAR-γ) gene (rs1801282) and the Peroxisome Proliferator-Activated Receptor-γ
Coactivator-1 (PGC-1α) gene (rs8192673) are associated with obesity indexes (BMI, waist circumference) in subjects
with type 2 diabetes mellitus (T2DM) in Caucasian population. The second aim was to find an association of both
polymorphisms with T2DM.
Methods: Two exonic SNPs of both genes rs1801282 of the PPAR-γ gene and rs8192673 of the PGC-1α gene)
were genotyped in 881 unrelated Slovene subjects (Caucasians) with T2DM and in 348 subjects without T2DM
(control subjects).
Results: Female homozygotes with the CC genotype of the rs8192673 had higher waist circumference in comparison
with subjects with other genotypes. Homozygotes (females, males) with wild allele (Pro) of the rs1801282 (Pro12Ala
polymorphism) had higher waist circumference in comparison with subjects with other genotypes. In the study, there
were no differences in the distributions of the rs8192673 and the rs1801282 genotypes between patients with T2DM
and controls. Linear regression analyses for both polymorphisms were performed and demonstrated an independent
effect of the rs1801282 of the PPAR-γ on waist circumference in subjects with T2DM, whereas an independent effect on
waist circumference was not demonstrated for the rs8192673 of the PGC-1α gene.
Conclusions: In a large sample of the Caucasians the rs8192673 of the PGC-1α gene and the rs1801282 of the PPAR-γ
gene were associated with waist circumference in subjects with T2DM.
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Diabetes mellitus (DM) is a multifactorial metabolic dis-
order, characterized by hyperglycemia, resulting from ab-
normalities in insulin secretion, insulin action, or both [1].
Diabetes prevalence has increased dramatically in many
countries over the past decades. The number of people with
diabetes exceeds 300 million worldwide, most of them be-
ing patients with type 2 diabetes mellitus (T2DM) and it
has become one of the most common chronic diseases in
the world. There are predictions, based on a large number
of studies, which indicate a growing burden of diabetes,
particularly in the developing countries [2-4].
There are several pathogenic mechanisms that influ-
ence the development of diabetes and its complications
[5-14]. T2DM is characterised by insulin resistance, dys-
function of pancreatic beta cells and enhanced hepatic
gluconeogenesis. However, the exact pathophysiology of
T2DM is still unknown. Abdominal obesity, sedentary
lifestyle, advancing age, genetic and epigenetic factors af-
fecting glucose homeostasis are thought to be key con-
tributing factors [15,16].
Peroxisome proliferator-activated receptor-γ coactivator-
1 (PGC-1α) gene is thought to be involved in three patho-
physiological hallmarks of T2DM: insulin sensitivity, insulin
secretion and hepatic gluconeogenesis [17,18]. Thus, func-
tional sequence substitutions in PGC-1α may play an im-
portant role in the development of T2DM.
Results of the association studies involving the rs8192673
of the PGC-1α gene and the rs1801282 of the PPAR-γ gene
published so far, reported different findings, showing either
an association with T2DM risk or no association
[16,18-22]. Moreover, the rs8192673 of the PGC-1α
gene was reported to be associated with insulin resist-
ance, obesity indices in women and with lipid metabol-
ism and insulin secretion [21,23,24].
Both the PPAR-γ gene and the PGC-1α gene are potential
candidates for modifying the risk of T2DM [6,8,25].
The aim of this study was to clarify whether common
single nucleotide polymorphisms of the PPAR-γ gene
(rs1801282) and the PGC-1α gene (rs8192673) are asso-
ciated with obesity indexes (BMI, waist circumference)
in subjects with T2DM in Caucasian population. The
second aim was to find an association of both polymor-
phisms with T2DM.
Materials and methods
In this cross-sectional study, 881 consecutive patients with
T2DM from the outpatients clinics for patients with dia-
betes from central and north-eastern regions of Slovenia
were enrolled as well as 348 subjects without diabetes. The
research protocol was approved by The National Medical
Ethics Committee. All the subjects enrolled in the study
were Slovenian and were not related. Patients were classi-
fied as having type 2 diabetes according to the currentreport of the American Diabetes Association [1]. After the
informed consent was obtained from the patient and sub-
jects, a detailed interview was made concerning smoking
habits, the duration and treatment of diabetes, arterial
hypertension, and hyperlipidemia. Patients were asked
whether they were smokers at the time of recruitment
(“current smoker”). The body mass index (BMI) was calcu-
lated as weight in kilograms divided by the height in square
meters. Obesity was determined defined as body mass
index ≥ 30 kg/ m2 [26].
Systolic blood pressure (SBP) and diastolic blood pressure
(DBP) in the right upper arm of the patients were measured
while they were sitting (2 consecutive measurements). Sub-
jects with T2DM with systolic blood pressure ≥ 140 mm Hg
or diastolic blood pressure ≥ 85 mm Hg and/or subjects
who were using antihypertensive drugs were considered
to be hypertensive [27]. Secondary causes of arterial
hypertension were excluded according to normal clin-
ical exam (no systolic murmur above renal arteries)
and normal serum electrolytes (exclusion of renal fail-
ure and hyperaldosteronism) [27].
Genomic DNA was extracted from 100 μl of whole
blood using a Qiagen isolation kit. Genotypes of PPAR-γ
were determined as described previously [28].
Blood samples for biochemical analyses: total choles-
terol, triglyceride levels, high-density lipoprotein (HDL),
low density lipoprotein (LDL) level and fasting blood
glucose were collected after an overnight fasting. All
blood biochemical analyses were determined by standard
biochemical methods in the hospital’s accredited lab.
Data are expressed as means ± standard deviations or
frequencies (percentages). The chi-square test was used to
compare discrete variables. Continuous clinical data were
compared by an unpaired Student’s t test (normal
distribution by Kolmogorov Smirnov test) or by Mann–
Whitney U test (for variables without normal distribution
by Kolmogorov Smirnov test) or analysis of variance. A
p < 0.05 was considered statistically significant. A statis-
tical analysis was performed using the SPSS program for
Windows version 20 (SPSS Inc. Illinois).
Continuous variables were expressed as means ± standard
deviations when normally distributed, and as median (inter-
quartile range) when asymmetrically distributed. Normality
was tested with the Kolmogorov–Smirnov test. Continuous
clinical data were compared by an unpaired Student’s t test
or analysis of variance (ANOVA) when normally distrib-
uted, and Mann–Whitney U-test or the Kruskal-Wallis
H-test when asymmetrically distributed. The Pearson ×2
test was used to compare discrete variables and to test
whether the genotypes distributions are in Hardy-
Weinberg equilibrium.
Pearson’s correlation was performed to examine the
association between independent variables. Due to the
high correlation of LDL cholesterol with total cholesterol
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the same statistical model.
For determination of variables independently associated
with waist circumference multivariate linear regression ana-
lyses were performed for both polymorphisms. Candidate
variables to enter the models were the following: age,
gender, plasma levels of LDL cholesterol and triglycerides,
hypolipemic therapy, diabetes therapy, HbA1c and geno-
types of the PPAR-γ (rs1801282) and the PGC-1α
(rs8192673) polymorphisms. The results were presented as
standardized ß coefficients and P-values for linear regres-
sion and by odds ratios and 95% CIs for logistic regression
analysis.
A two-tailed P value less than 0.05 was considered sta-
tistically significant. A statistical analysis was performed
using the SPSS program for Windows version 20 (SPSS
Inc., Chicago, IL).
Results
Clinical characteristics of the cases (patients with T2DM)
and controls (subjects without T2DM) are summarized in
Table 1. Cases had higher frequency of arterial hyperten-
sion, obesity (defined as body mass index ≥ 30 kg/ m2) inTable 1 Characteristics of subjects with type 2 diabetes
(cases) and in subjects without diabetes (controls)
Characteristics Cases Controls P
Number 881 348 -
Age (years) 63.2 ± 10.3 61.3 ± 12.9 0.1
Male sex (%) 458 (52.0) 173 (49.7) 0.3
Duration of diabetes (years) 14.8 ± 8.9 - -
Incidence of arterial hypertension (%) 458 (52.0) 103 (29.6) <0.001
Systolic blood pressure (mm Hg) 148.9 ± 28.5 146.7 ± 22.7 0.06
Diastolic blood pressure (mm Hg) 84.9 ± 12.2 83.5 ± 11.8 0.3
BMI (kg/m2)1 30.4 ± 4.2 28.5 ± 3.5 <0.001
Obesity2 436 (49.5) 87 (25.0) <0.001
Smokers (%) 61 (6.9) 45 (12.9) <0.001
Glucose (mmol/l) 8.32 ± 2.52 5.18 ± 0.87 <0.001
Hba1c3 8.07 ± 1.54 - -
hsCRP (mg/l)4* 2.1 (1.0-4.1) 1.1 (0.6-2.7) <0.001
Fibrinogen (g/l) 4.10 ± 1.15 3.76 ± 0.83 <0.001
Hypolipemic drugs 698 (79.2) 66 (19.0) <0.001
Total cholesterol (mmol/l) 5.5 ± 1.4 5.9 ± 1.6 <0.001
HDL cholesterol (mmol/l) 1.1 ± 0.3 1.3 ± 0.4 <0.001
LDL cholesterol (mmol/l) 2.6 ± 0.9 3.0 ± 1.1 <0.001
Triglycerides (mmol/l)* 1.9 (1.2-2.7) 1.3 (0.9-1.9) <0.001
Continuous variables were expressed as means ± standard deviations when
normally distributed and as median (interquartile range) when asymmetrically
distributed.
1BMI – body mass index, 2obesity is defined as BMI ≥ 30 kg/m2, 3Hba1c – glycated
hemoglobin A1c, 4hsCRP – high sensitive C reactive protein, *Continuous variables
with asymmetric distribution.comparison with controls (Table 1). The values of body
mass index (BMI), glucose, high sensitive C reactive protein
(hsCRP), lipid parameters, fibrinogen levels were higher in
subjects with T2DM. Additionally they had a higher
frequency of hypolipemic therapy with higher values of
triglycerides. On the contrary, total cholesterol, LDL
cholesterol, and HDL cholesterol levels were higher in
control subjects, as well as the percentage of current
smokers. Results show no statistical significant differ-
ences in age and blood pressure values between cases
and controls (Table 1).
The genotypes of both polymorphisms were in Hardy–
Weinberg equilibrium (rs1801282 cases: ×2 = 3.22, p = 0.07;
controls: ×2 = 0.56, p = 0.45; rs1801282 cases: ×2 = 0.07,
p = 0.79; controls: ×2 = 2.5, p = 0.11).
The distribution of PPAR-γ gene (rs1801282) and the
PGC-1α gene (rs8192673) among patients with T2DM
and control subjects without T2DM is shown in Table 2.
There were no differences in the distributions of the
rs8192673 and the rs1801282 genotypes between pa-
tients with T2DM and control subjects without T2DM
(Table 2).
The rs8192673 polymorphism was associated with waist
circumference in subjects with T2DM. Specifically, female
homozygotes with mutated allele (CC genotype) had higher
waist circumference in comparison with subjects with other
genotypes (Figure 1). Moreover, the rs1801282 (Pro12Ala
polymorphism) polymorphism was associated with waist
circumference in subjects with T2DM. Namely, subjects
with the CC genotype (men and women, men, women) hadTable 2 Genotype distribution and allele frequencies of
the rs8192673 of the PGC-1α gene and rs1801282 of the
PPAR-γ gene in subjects with T2DM and in control subjects
Polymorphism T2DM n = 881 Controls n = 348 p
rs8192673
TT 467 (53.0) 161 (46.3)
TC 334 (37.9) 147 (42.2) 0.08
CC 80 (9.1) 40 (11.5)
Allele frequencies
T 1268 (71.9) 469 (67.4) 0.02
C 494 (28.1) 227 (32.6)
rs1801282
CC 631 (71.6) 250 (71.8) 0.50
CG 228 (25.9) 85 (24.5)
GG 22 (2.5) 13 (3.7)
Allele frequencies
C 1490 (84.6) 585 (84.1) 0.06
G 272 (15.4) 111 (15.9)
Results were presented as frequency (percentage).
Figure 1 Waist circumference (cm) with regard to rs8192673 genotypes of the PGC-1α gene.
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with other genotypes (Figure 2).
Linear regression analyses for both polymorphisms
were performed and demonstrated an independent effect
of the rs1801282 of the PPAR-γ on waist circumference
in subjects with T2DM, whereas an independent effect
on waist circumference was not demonstrated for the
rs8192673 of the PGC-1α gene (Table 3).Figure 2 Waist circumference (cm) with regard to rs1801282 genotypes ofDiscussion
In this cross-sectional association study that involved
more than one thousand Caucasians, the rs8192673 of
the PGC-1α gene and the rs1801282 of the PPAR-γ gene
failed to be associated with T2DM. These findings differ
from an early report in the Slovene population from
2004 [28] and from the report from another Caucasian
population [18], in which the authors reported a linkthe PPAR-γ gene.
Table 3 Multivariate linear regression analyses for
variables independently associated with waist
circumference for both polymorphisms (rs8192673 of the
PGC-1α gene, rs1801282 of the PPAR-γ)
rs8192673 of the PGC-1α gene
β p
Age (year) −0.09 <0.001
Gender (0 = male, 1 = female) −1.179 0.019
Triglycerides (mmol/L) 0.684 <0.001
LDL cholesterol (mmol/L) 0.288 0.759
HbA1c (%) 0.013 0.957
Insulin therapy (0 = no, 1 = yes) −0.864 0.101
Hypolipemic therapy (0 = no, 1 = yes) −0.479 0.786
TC* 0.537 0.271
CC* 0.646 0.54
rs1801282 of the PPAR-γ
Age (year) −0.007 0.807
Gender (0 = male, 1 = female) −1.213 0.016
Triglycerides (mmol/L) −0.698 <0.001
LDL cholesterol (mmol/L) −0.269 0.759
HbA1c (%) 0.134 0.954
Insulin therapy (0 = no, 1 = yes) −0.812 0.122
Hypolipemic therapy (0 = no, 1 = yes) 0.550 0.755
CG** −0.673 0.024
GG** −0.832 0.035
*Reference genotype was TT; **Reference genotype was CC.
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The present finding in the Slovene population is in
accordance with few other reports in the Caucasians
[16,20], the Japanese population [21] and the Pima
Indians [22], which also failed to demonstrate an associ-
ation with T2DM. Moreover, rs1801282 (Pro12Ala poly-
morphism) of the PPAR-γ was also implicated in several
studies to affect the T2DM risk [29]. Mekhani and co-
workers reported that in the Iranian population there
was a lower frequency of Ala allele in subjects with
T2DM when these were compared to control subjects
without T2DM (5.9% vs. 9.4%, p = 0.005). Besides being
associated with a decreased risk of T2DM, this poly-
morphism was also associated with greater insulin sensi-
tivity [28]. In the present study carried out in the
Slovene population with T2DM there was no statistically
significant difference in allele distribution, the frequency
of the Ala allele was 15.4% and 15.9% in subjects with
T2DM and in controls, respectively.
Due to some reports of an association of both poly-
morphisms (rs8192673, rs1801282) with obesity indexes
[18,24,29], the influence of both polymorphisms on
obesity indexes (BMI, waist circumference) in subjects
with T2DM was also examined. In the present study inSlovene subjects with T2DM, the homozygous females
with wild alleles had lower waist circumference in com-
parison with homozygous females with mutated alleles,
whereas the effect of the rs8192673 genotypes was not
demonstrated in males with T2DM. This finding is in
accordance with an early report by Esterbauer and co-
workers on general population [24]. They reported that
wild allele was associated with lower waist circumference
in middle-aged women, whereas there was no associ-
ation between rs8192673 alleles in middle-aged men.
Contrary to these reports, Ek and co-workers failed to
report an association with another obesity index, namely
BMI in their male/female type 2 diabetes and control
populations [18,24]. In the present study, the rs1801282
(Pro12Ala polymorphism) polymorphism was also asso-
ciated with waist circumference in subjects with T2DM.
Namely, homozygotes (females, males) with wild allele
(Pro) had higher waist circumference in comparison
with subjects with other genotypes. Moreover, linear
regression analyses for both polymorphisms were per-
formed and demonstrated an independent effect of the
rs1801282 of the PPAR-γ on waist circumference in
subjects with T2DM, whereas an independent effect on
waist circumference was not demonstrated for the
rs8192673 of the PGC-1α gene. Contrary to our study,
the Pro12Ala polymorphism did not show a significant
effect on anthropometric and biochemical parameters in
Iranian subjects with T2DM [29].
The exact mechanism of both polymorphisms is not
completely clear, but they are expected to have various
effects including affecting the insulin sensitivity of per-
ipheral organs [11,23]. However, despite being associated
with some obesity markers in this study and in several
other studies, the influence of both polymorphisms is
not strong enough to be associated with increased risk
of T2DM [18,24,29]. Interactions among genetic (gene
variants) and/or clinical factors (physical inactivity, diet,
obesity…), which may have stronger effects in combin-
ation, are expected to increase the power of risk predic-
tion of multifactorial disorders (including T2DM) and
advance our understanding of the underlying biology of
multifactorial disorders [2,3,30,31].
Beside these two polymorphisms of the PGC-1α and the
PPAR-γ genes (rs8192673 and rs1801282) several other
genes have been so far implicated by linkage analysis, asso-
ciation studies, and genome-wide association studies in the
development of obesity and obesity-associated phenotypes
[32-38]. Proteasome modulator 9 (PSMD9) gene was
reported to be responsible for the linkage to obesity and
obesity-associated phenotypes (waist circumference, over-
weight status) at the locus 12q24 [33]. Frayling and co-
workers showed for the first time the contribution of the
SNP rs9939609 in fat mass and obesity-associated gene
FTO on excess of weight [37]. Common genetic variants of
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rs17782313 of the melanocortin 4 receptor (MC4R) gene
with neck circumference in women [32]. Mutation in
MC4R gene was found to be associated with morbid obes-
ity in human beings [38]. Recently the association between
the Fas apoptotic inhibitory molecule 2 (FAIM2)-rs7138803
polymorphism and greater obesity risk has been replicated
[35]. Moreover, rs6232 of the proprotein convertase subtili-
sin/kexin-type 1 (PCSK1) was associated BMI [34]. Several
different mechanisms of action have been proposed
[32-36]. PCSK1 was found to activate precursors pro-
opiomelanocortin (POMC), proinsulin and prorenin (citat).
Similarly, since PSMD9 is a coactivator of insulin gene tran-
scription, and in pancreatic overexpression of transgenic
mice cause diabetes, PSMD9 variants may contribute to
T2DM as well as to obesity [33,39,40]. Moreover, miRNA-
dependent regulation of fat distribution by miR-196a2 and
miR-1908-dependent regulation of lipid metabolism has re-
cently been reported [36]. Additionally, according to the
study of Corella and co-workers epigenetic factors may also
be involved in the development of obesity [35].
Our study has few limitations, one of them being the
cross-sectional design of the study. One of the major limita-
tions of the current study is the absence of a replication
study with independent samples. Another weakness is a
relatively limited sample size. However, all the participants
were enrolled from an ethnically homogenous population.
Thus further studies are needed to replicate our findings in
different ethnic groups with a larger sample size.
In conclusion, in a large sample of the Caucasians the
rs8192673 of the PGC-1α gene and the rs1801282 of the
PPAR-γ gene were associated with waist circumference
in subjects with T2DM.
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